{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:01:49Z","timestamp":1785441709328,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.transci.2026.104490","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:01:56Z","timestamp":1783468916000},"page":"104490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of G-CSF alone versus G-CSF combined with different doses of cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0346-7154","authenticated-orcid":false,"given":"Mesut","family":"G\u00f6\u00e7er","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdal","family":"Kurto\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.transci.2026.104490_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.transci.2026.104490_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, ran- domized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2026.104490_bib3","series-title":"Autologous and allogeneic transplantation in the novel agent era Hematology Education: the education programme for the annual congress of the European Hematology Association","first-page":"229","author":"Cavo","year":"2012"},{"key":"10.1016\/j.transci.2026.104490_bib4","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Prim"},{"issue":"3","key":"10.1016\/j.transci.2026.104490_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.transci.2026.104490_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103830","article-title":"Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection","volume":"62","author":"Lanza","year":"2023","journal-title":"Transfus Apher Sci"},{"issue":"7","key":"10.1016\/j.transci.2026.104490_bib7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.transci.2026.104490_bib8","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.transci.2026.104490_bib9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jca.21360","article-title":"Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"30","author":"Tuchman","year":"2015","journal-title":"J Clin Apher"},{"issue":"2","key":"10.1016\/j.transci.2026.104490_bib10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00277-021-04427-w","article-title":"Correction to: Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis","volume":"100","author":"Wang","year":"2021","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.transci.2026.104490_bib11","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41409-018-0152-2","article-title":"Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma","volume":"53","author":"Chua","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.transci.2026.104490_bib12","doi-asserted-by":"crossref","first-page":"590.e1","DOI":"10.1016\/j.jtct.2021.04.016","article-title":"Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +\/- plerixafor versus granulocyte colony-stimulating factor +\/- plerixafor in the lenalidomide era","volume":"27","author":"Johnsrud","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.transci.2026.104490_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102819","article-title":"A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: an Italian explorative cost Analysis","volume":"59","author":"Laszlo","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"5","key":"10.1016\/j.transci.2026.104490_bib14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/ejh.13693","article-title":"Safety of outpatient stem cell mobilization with low- or intermediate-dose cyclophosphamide in newly diagnosed multiple myeloma patients","volume":"107","author":"Pompa","year":"2021","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.transci.2026.104490_bib15","doi-asserted-by":"crossref","first-page":"244.e1","DOI":"10.1016\/j.jtct.2020.12.009","article-title":"Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.transci.2026.104490_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2025.104183","article-title":"A comparison of cyclophosphamide at different dose levels for stem cell mobilization in multiple myeloma","volume":"64","author":"Karakus","year":"2025","journal-title":"Transfus Apher Sci"},{"issue":"5","key":"10.1016\/j.transci.2026.104490_bib17","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/trf.17829","article-title":"Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: a single-center retrospective analysis","volume":"64","author":"Dill","year":"2024","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.transci.2026.104490_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.transci.2026.104490_bib19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","article-title":"Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation","volume":"14","author":"Pusic","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.transci.2026.104490_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2024.103931","article-title":"Novel approaches for hematopoietic stem cell mobilisation and collection need to be assessed for qualification and validation to accomplish the proper requirements of their intended purpose","volume":"63","author":"Lanza","year":"2024","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.transci.2026.104490_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2011.197","article-title":"Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4","volume":"26","author":"Rettig","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.transci.2026.104490_bib22","doi-asserted-by":"crossref","first-page":"873","DOI":"10.5966\/sctm.2015-0015","article-title":"Autologous hematopoietic stem cell transplantation-10 years of data from a developing country","volume":"4","author":"Ali","year":"2015","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"10.1016\/j.transci.2026.104490_bib23","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/cells13100853","article-title":"Multiple myeloma: the role of autologous stem cell transplantation in the era of immunotherapy","volume":"13","author":"Rocchi","year":"2024","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.transci.2026.104490_bib24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ajh.21552","article-title":"Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma","volume":"84","author":"Nakasone","year":"2009","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.transci.2026.104490_bib25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.bbmt.2012.01.008","article-title":"Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies","volume":"18","author":"Sheppard","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.transci.2026.104490_bib26","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2012.01.005","article-title":"Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies","volume":"18","author":"Hamadani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.transci.2026.104490_bib27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1172\/JCI15994","article-title":"Disruption of the CXCR4\/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide","volume":"111","author":"L\u00e9vesque","year":"2003","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.transci.2026.104490_bib28","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/bmt.2013.80","article-title":"Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone","volume":"48","author":"Sung","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.transci.2026.104490_bib29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00277-023-05170-0","article-title":"Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments","volume":"102","author":"Wei","year":"2023","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.transci.2026.104490_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41409-017-0051-y","article-title":"Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score","volume":"53","author":"Olivieri","year":"2018","journal-title":"Bone Marrow Transplant"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050226001229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050226001229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:30:15Z","timestamp":1785439815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050226001229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1473050226001229"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2026.104490","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of G-CSF alone versus G-CSF combined with different doses of cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2026.104490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104490"}}